{
    "2019-12-16": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Why this company ponied up $99M for a mid-Peninsula building",
                "features": {
                    "keywords": [
                        "company",
                        "ponied up",
                        "$99M",
                        "mid-Peninsula building"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "real estate",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "This Biotech Just Gave Up A Breakout — Why An Analyst Is Still Bullish",
                "features": {
                    "keywords": [
                        "biotech",
                        "breakout",
                        "analyst",
                        "bullish"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Amarin’s fish-oil pill now available to millions more patients. But it’s still no Lipitor",
                "features": {
                    "keywords": [
                        "Amarin",
                        "fish-oil pill",
                        "patients",
                        "Lipitor"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-12",
                "original_text": "Regeneron Stock Is Downgraded. Analyst Cites Tough Competition From a Novartis Drug.",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "stock",
                        "downgraded",
                        "Novartis",
                        "competition"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-07-05",
                "original_text": "Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CHMP",
                        "opinion",
                        "AMD",
                        "Beovu"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "There’s more upside for biotech even after 24% gains in two months",
                "features": {
                    "keywords": [
                        "upside",
                        "biotech",
                        "gains"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}